Angelalign Technology (SEHK:6699) Faces A Europe Patent Setback As Valuation Questions Grow

Simply Wall St.10-31

Angelalign Technology (SEHK:6699) is under fresh scrutiny after the Paris Local Division of the Unified Patent Court ruled that its Torque Ridges aligner systems infringe an Align Technology patent, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2679273053?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice1-card/1788954194987","is_english":true,"pubTime":"2026-10-31 15:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2679273053","market":"us","top_or_hot":-1,"title":"Angelalign Technology (SEHK:6699) Faces A Europe Patent Setback As Valuation Questions Grow","media":"Simply Wall St.","content":"<div>\n<p>Angelalign Technology (SEHK:6699) is under fresh scrutiny after the Paris Local Division of the Unified Patent Court ruled that its Torque Ridges aligner systems infringe an Align Technology patent, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-6699/angelalign-technology-shares/news/angelalign-technology-sehk6699-faces-a-europe-patent-setback\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Angelalign Technology (SEHK:6699) Faces A Europe Patent Setback As Valuation Questions Grow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngelalign Technology (SEHK:6699) Faces A Europe Patent Setback As Valuation Questions Grow\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-31 15:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/healthcare/hkg-6699/angelalign-technology-shares/news/angelalign-technology-sehk6699-faces-a-europe-patent-setback><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Angelalign Technology (SEHK:6699) is under fresh scrutiny after the Paris Local Division of the Unified Patent Court ruled that its Torque Ridges aligner systems infringe an Align Technology patent, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-6699/angelalign-technology-shares/news/angelalign-technology-sehk6699-faces-a-europe-patent-setback\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-6699/angelalign-technology-shares/news/angelalign-technology-sehk6699-faces-a-europe-patent-setback","article_id":"2679273053","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice1-card/1788954194987"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-6699/angelalign-technology-shares/news/angelalign-technology-sehk6699-faces-a-europe-patent-setback","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2679273053","pubTimestamp":1793431471,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Angelalign Technology (SEHK:6699) is under fresh scrutiny after the Paris Local Division of the Unified Patent Court ruled that its Torque Ridges aligner systems infringe an Align Technology patent, triggering injunctions and product recalls across multiple EU countries.\nAngelalign Technology’s legal hit in Europe lands after a mixed run in the market, with the latest share price at HK$76.55 and a year-to-date share price return of 25.7%. The 1-year total shareholder return of 34.45%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1593":"医美概念股","BK1587":"次新股","VOTE":"TCW Transform 500 ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","06699":"时代天使","JOYT":"JPMorgan Equity and Options Total Return ETF","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","RGLO":"Global Equity Active ETF","BK1583":"高瓴概念","VGFPF":"Vanguard Funds PLC","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","BK1100":"医疗保健设备","GXDW":"Global X Dorsey Wright Thematic ETF"},"translate_title":"随着估值问题加剧，Angelalign Technology (SEHK:6699) 面临欧洲专利挫折","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FEBU":0.86,"06699":0.9,"VGFPF":0.86,"VOTE":0.86,"DECU":0.86,"RGLO":0.86,"PMDE":0.86,"JOYT":0.86,"DCF":1,"GXDW":0.86},"content_text":"Angelalign Technology (SEHK:6699) is under fresh scrutiny after the Paris Local Division of the Unified Patent Court ruled that its Torque Ridges aligner systems infringe an Align Technology patent, triggering injunctions and product recalls across multiple EU countries. Angelalign Technology’s legal hit in Europe lands after a mixed run in the market, with the latest share price at HK$76.55 and a year-to-date share price return of 25.7%. The 1-year total shareholder return of 34.45% contrasts with a much weaker 5-year total shareholder return that declined 71.45%, which hints that recent momentum has improved from a low base. At the same time, the past month’s 10.36% share price pullback and 7-day share price return that fell 5.73% suggest investors are now reassessing risk as litigation headlines build. Scan beyond Angelalign Technology and stress test your dental and medical holdings against our curated list of solid balance sheet and fundamentals (203 results), which includes companies with the financial cushion to absorb regulatory and legal shocks. After a sharp rebound from deep losses and a fresh legal overhang from Europe, Angelalign Technology now sits at a crossroads. Does the current valuation still compensate you for this legal and operational risk? AdvertisementPreferred P/E of 40.6x: Is it justified for Angelalign Technology? On simple earnings multiples, Angelalign Technology trades on a P/E of 40.6x, which is a rich tag relative to much of the Hong Kong Medical Equipment sector. The P/E ratio compares the current share price to earnings per share and gives you a quick sense of how much investors are paying for each unit of profit. For a specialist dental equipment and services business like Angelalign Technology, that valuation anchor matters because earnings are closely watched as a proxy for how well the aligner and clinic model is converting demand into bottom line results. Recent numbers show earnings growth of 74% over the past year and revenue growth of 16.1% annually, with current net profit margins at 9.3% compared with 7.6% last year. Forecasts point to earnings increasing 31.1% per year and revenue rising 16.1% per year, which suggests the market is paying up for a stronger profit trajectory after a difficult 5 year stretch where earnings declined 10% per year. Set against peers, that 40.6x P/E is more than double the Hong Kong Medical Equipment industry average of 18x and above the peer average of 19.1x. It is also comfortably higher than the estimated fair P/E of 18.6x, which is the level the market could move towards if sentiment cools on the current growth story. Explore the SWS fair ratio for Angelalign Technology. Result: Price-to-earnings of 40.6x (OVERVALUED) Still, Angelalign Technology now faces the Unified Patent Court ruling and ongoing product recalls, which could weigh on earnings visibility and investor confidence if disruption widens. Find out about the key risks to this Angelalign Technology narrative. Another View: What Our DCF Model Says About Angelalign Technology The high P/E ratio paints Angelalign Technology as expensive, yet the SWS DCF model tells a very different story. On estimated future cash flows, the stock trades at HK$76.55 compared with a DCF fair value of HK$134.32, which points to a 43% discount. That gap suggests the current price reflects a lot of uncertainty around legal risk and earnings durability. It raises a simple question for you as an investor: Is the market being too harsh on Angelalign Technology, or is the model too optimistic about future cash generation? Look into how the SWS DCF model arrives at its fair value. 6699 Discounted Cash Flow as at Oct 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Angelalign Technology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 199 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Sentiment around Angelalign Technology is split, which is exactly when it helps to move fast and test the data yourself before views harden. To weigh the upside against the legal and operational questions, start with the 4 key rewards and 2 important warning signs. Looking for more Angelalign Technology investment ideas? Do not stop your research with Angelalign Technology. Broaden your watchlist with focused stock ideas that fit different goals, risk levels, and income needs using the Simply Wall St Screener.  Target potential mispricing by scanning for quality companies trading at attractive valuations through the 199 high quality undervalued stocks. Build a steadier portfolio by focusing on payout strength and income resilience with the 221 dividend fortresses. Dial down portfolio stress by concentrating on financially sturdy businesses using the 218 resilient stocks with low risk scores.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2679273053","isCrawlerRequest":true}